cuminol: an insulinotropic agent with protective activity toward beta-cells; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
4-isopropylbenzyl alcohol : A member of the class of benzyl alcohols in which the hydrogen at position 4 on the phenyl ring of benzyl alcohol has been replaced by an isopropyl group. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| ID Source | ID |
|---|---|
| PubMed CID | 325 |
| CHEMBL ID | 3183500 |
| CHEBI ID | 27628 |
| SCHEMBL ID | 113930 |
| MeSH ID | M0590637 |
| Synonym |
|---|
| HMS1789P06 |
| v261w8xr62 , |
| unii-v261w8xr62 |
| C0376 |
| 4-(1-methylethyl)benzene methanol |
| (4-isopropylphenyl)methanol |
| ai3-20440 |
| brn 0636665 |
| fema no. 2933 |
| einecs 208-640-4 |
| 4-(1-methylethyl)benzenemethanol |
| nsc 15672 |
| benzyl alcohol, p-isopropyl- |
| wln: q1r dy1&1 |
| cuminol |
| p-isopropylbenzyl alcohol |
| benzenemethanol, 4-(1-methylethyl)- |
| cumin alcohol |
| nsc15672 |
| nsc-15672 |
| cumic alcohol |
| p-cymen-7-ol |
| cumyl alcohol |
| p-isopropyl benzyl alcohol |
| C06576 |
| cuminyl alcohol |
| 4-(1-methylethyl)-benzenemethanol |
| p-cumic alcohol |
| 4-isopropylbenzyl alcohol |
| cuminic alcohol |
| 536-60-7 |
| inchi=1/c10h14o/c1-8(2)10-5-3-9(7-11)4-6-10/h3-6,8,11h,7h2,1-2h3 |
| oigwaxdapkfncq-uhfffaoysa- |
| 4-isopropylbenzyl alcohol, >=97%, fg |
| 4-isopropylbenzyl alcohol, 97% |
| cuminylalcohol |
| BMSE000599 |
| 4-isopropylbenzenemethanol |
| I0272 |
| (4-propan-2-ylphenyl)methanol |
| AKOS000121600 |
| NCGC00249151-01 |
| [4-(propan-2-yl)phenyl]methanol |
| tox21_302797 |
| dtxsid0021626 , |
| cas-536-60-7 |
| dtxcid301626 |
| NCGC00256602-01 |
| NCGC00259574-01 |
| tox21_202025 |
| FT-0618835 |
| FT-0624114 |
| cumic alcohol [mi] |
| p-isopropylbenzyl alcohol [fhfi] |
| isopropylbenzyl alcohol, p- |
| S5090 |
| SCHEMBL113930 |
| para-cymen-7-ol |
| (4-isopropylphenyl)methanol # |
| p-cymene-7-ol |
| CHEMBL3183500 |
| mfcd00004663 |
| AS-59256 |
| cuminol ( p-cymen-7-ol) |
| 4-isopropyl benzyl alcohol |
| 4-(1-methylethyl)benzenemethanol, 9ci |
| p-cymen-7-ol, 8ci |
| fema 2933 |
| p-isopropyl-benzyl alcohol |
| p-cumin-7-ol |
| p-mentha-1,3,5-trien-7-ol |
| CHEBI:27628 |
| HY-N7069 |
| 4-isopropyl-benzyl alcohol |
| Q1143803 |
| CCG-266208 |
| CS-W018138 |
| D97386 |
| Z56347221 |
| Role | Description |
|---|---|
| fragrance | A substance, extract, or preparation for diffusing or imparting an agreeable or attractive smell. |
| insect repellent | An insecticide that acts as a repellent to insects. |
| volatile oil component | Any plant metabolite that is found naturally as a component of a volatile oil. |
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| xenobiotic metabolite | Any metabolite produced by metabolism of a xenobiotic compound. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Class | Description |
|---|---|
| benzyl alcohols | Compounds containing a phenylmethanol skeleton. |
| p-menthane monoterpenoid | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
| Pathway | Proteins | Compounds |
|---|---|---|
| p-cymene degradation | 14 | 21 |
| p-cymene degradation to p-cumate | 3 | 9 |
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 15.3553 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377 |
| retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 10.7527 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
| estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 41.4102 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1259401 |
| estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 49.0376 | 0.0002 | 29.3054 | 16,493.5996 | AID743075; AID743077; AID743079 |
| peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 27.5425 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
| thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 0.0069 | 0.0016 | 28.0151 | 77.1139 | AID1259385 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1198410 | Fungicidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 48 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198415 | Cytotoxicity against African green monkey Vero cells assessed as reduction in cell viability after 48 hrs by neutral red assay | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198412 | Fungicidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 48 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198414 | Fungicidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 48 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198409 | Anticandidal activity against Candida albicans ATCC 90028 incubated at 37 degC for 24 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198413 | Anticandidal activity against Candida tropicalis ATCC 750 incubated at 37 degC for 24 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID1198411 | Anticandidal activity against Candida glabrata ATCC 90030 incubated at 37 degC for 24 hrs by broth dilution method | 2015 | European journal of medicinal chemistry, Mar-26, Volume: 93 | Synthesis, QSAR and anticandidal evaluation of 1,2,3-triazoles derived from naturally bioactive scaffolds. |
| AID588519 | A screen for compounds that inhibit viral RNA polymerase binding and polymerization activities | 2011 | Antiviral research, Sep, Volume: 91, Issue:3 | High-throughput screening identification of poliovirus RNA-dependent RNA polymerase inhibitors. |
| AID540299 | A screen for compounds that inhibit the MenB enzyme of Mycobacterium tuberculosis | 2010 | Bioorganic & medicinal chemistry letters, Nov-01, Volume: 20, Issue:21 | Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 4 (66.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be very strong demand-to-supply ratio for research on this compound.
| This Compound (62.86) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 1 (16.67%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 5 (83.33%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||